Apraclonidine

Apraclonidine 1% w/v Eye Drops, Solution is indicated to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. (Clinical trials have been conducted in trabeculoplasty, iridotomy and capsulotomy).

5% w/v and 1% w/v (as apraclonidine hydrochloride) Benzalkonium chloride as preservative. For a complete listing see Dosage Forms, Composition and Packaging section. INDICATIONS AND CLINICAL USE IOPIDINE® 1% IOPIDINE 1% (apraclonidine ophthalmic solution) is indicated for the control or prevention of postsurgical elevations in intraocular pressure (IOP) that occur in patients after anterior segment laser ophthalmic surgery including argon laser trabeculoplasty, argon laser iridotomy and neodymium:yttrium aluminum garnet (Nd:YAG) laser posterior capsulotomy.

5% (apraclonidine ophthalmic solution) is indicated for adjunctive use in lowering intraocular pressure (IOP) and may be used as a short-term therapy in glaucoma patients on maximally tolerated medical therapy who require an additional IOP reduction.

The largest body of clinical data regarding the efficacy of apraclonidine as an adjunctive drug has been obtained in patients using timolol as the primary therapy. Apraclonidine has also been found to be effective in combination with topical betaxolol, carbachol, dipivefrin, echothiophate, epinephrine, levobunolol and pilocarpine and systemic acetazolamide and methazolamide.

INDICATIONS AND USAGE

5% is indicated for short-term adjunctive therapy, in patients on maximally tolerated medical therapy, who require additional IOP reduction. 5% to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the IOP rises significantly.

, beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. 5% is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP.

5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month.